are few studies that clarify the morbidity of dementia among diabetic patients. In our clinic-based study, we examined the percentage of patients with impaired cognitive function among elderly diabetic outpatients.
Research Design and Methods

Subjects
We recruited 240 consecutive outpatients with type 2 diabetes mellitus attending the Department of Diabetes and Endocrinology at Tokyo Medical University Hospital from October 2005 to March 2007. All patients gave written informed consent, and the study protocol was approved by the Ethics Review Board of Tokyo Medical University. Patients with definite cognitive impairment (CI), cerebrovascular disease, other central nervous system disorders or psychiatric diseases were excluded from this study. At first, cognitive function in all patients was assessed using the Mini-Mental State Examination (MMSE). We divided the patients into 3 groups according to MMSE score: normal cog-
Statistical analysis
We analyzed the differences in clinical backgrounds between the group with normal MMSE scores (28 to 30 points) and the group with scores below the normal MMSE range (27 points or less), using one-way analysis of variance. The significance level was set at P < 0.05.
Results
Subject profiles are shown in Table 2 . There were 130 men (mean age ±SD, 75 ± 5.2 years) and 110 women (75 ± 5.1 years). The mean age ± SD of the entire subject population was 75 ± 5.2 years. The average duration of diabetes in the subjects was 16 ± 8.1 years. The distribution of treatments in the patients was as follows: 66 subjects (27.5%) were on a diet and exercise regime only; 107 subjects (44.7%) were on oral antidinitive function group (NC, MMSE score 28-30), suspected cognitive impairment group (sCI, MMSE score 24-27), and definite cognitive impairment group (dCI, MMSE ≤ 23). Next, the patients in the sCI and dCI groups underwent detailed general physical, neurologic, and psychiatric examinations by geriatric neurological specialists, extensive laboratory tests, and either brain computed tomography (CT), magnetic resonance imaging (MRI), or perfusion single photon emission CT (SPECT) to determine the causes of CI, such as AD, VaD, MCI, and other diseases. In addition, neuropsychological tests, including the Wechsler Memory Scale-revised (WMS-R) logical memory-I and -II tests, Alzheimer's disease Assessment Scale -cognitive subscale Japanese version (ADAS-Jcog) [5] , and Frontal Assessment Battery test, were performed by neuropsychometric specialists in patients with sCI and dCI.
The diagnosis of AD was based on the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association [6] . In the present study, patients with AD who had a Clinical Dementia Rating score (CDR) of 0.5 and a MMSE score of 24 or more were defined as early AD. A diagnosis of amnestic mild cognitive impairment (MCI) was made using the following criteria [7] : 1) memory complaints by patient or family; 2) normal activities of daily living; 3) normal global cognitive function; 4) objective impairment in memory as evident by scores > 1.5 standard deviation (SD) below the age-appropriate mean; 5) CDR score of 0.5; and 6) absence of dementia. A diagnosis of VaD was based on the criteria of National Institute of Neurological Disorders and Stroke, and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences [8] . We categorized the degree of cognitive impairment in these patients into stages, as shown in Table 1 . 
Relationship between results of MMSE and clinical backgrounds
We investigated differences in clinical backgrounds between the following 2 groups: the group of subjects with normal scores on MMSE (28 to 30 points), and the group of subjects with scores below the normal range on MMSE (27 points or less) (Tables 3 and 4) .
Analysis revealed that lower scores on MMSE were associated with habitual drinking, history of cerebrovascular disease, and use of diuretics. In terms of their relation to clinical laboratory parameters, the serum levels of total cholesterol and non-high-density lipoprotein (HDL)-cholesterol were higher, and the serum potassium levels lower, in the low MMSE score group.
Discussion
Although many reports have linked diabetes with CI, there are few studies that have attempted to clarify the morbidity of CI among elderly diabetic patients. We set out to determine this association. At least 5% of patients received a diagnosis of evident dementia, including early AD in 5 people, among 240 elderly diabetic patients in whom family and medical staff had not noticed any CI. This rate is higher than the global data collected from a population of 60 years or older in the Delphi consensus study [9] . However, we consider abetic medication; 67 subjects (27.9%) were on treatment with insulin. There were 68 (28.3%) smokers and 77 (32.1%) habitual drinkers. The most frequently prescribed antihypertensive drugs were angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors, followed by Ca channel blockers. Diuretics were also prescribed in 24 subjects (10%). The average blood pressure was 138 ± 18 / 72 ± 10 mm Hg.
MMSE results and final diagnoses
The MMSE results are shown in Fig. 1 . A total of 151 subjects (63%) scored 28 to 30 points, which is recognized as normal; 77 subjects (32%) scored 24 to 27 points, which is considered to represent some degree of CI, and 12 subjects (5%) scored 23 points or less, which is considered to be almost diagnostic of dementia.
Among the 12 subjects who scored 23 points or less, 8 agreed to be examined by dementia specialists. Of these, 5 were given diagnoses of AD, 2 of VaD, and 1 of mixed dementia. Twenty-four of the 77 subjects who scored 24 to 27 points on MMSE also agreed to receive a similar examination by specialists; 5 were given diagnoses of early AD, 10 of cerebrovascular disease (CVD), 7 of MCI, and 2 were considered to have no CI.
Fig. 1 Survey procedure and final diagnosis
Flowchart of the study population tool for CI, is a simple-to-apply scale that is globally adopted [16] . The following cutoff scores were recommended: ≥ 24 points = no dementia; ≤ 23 points = suspected dementia. Numerous previous studies reported the sensitivity of the MMSE to be 44% to 100% (mean, 75%) for the diagnosis of dementia [17] . However, in the present study 24 patients received close examination with a MMSE score of 24 to 27 points, but only 2 were given a final diagnosis of normal cognitive function, showing that care is necessary when setting the cutoff value in applying the MMSE to diabetic patients. Based on the current results, we propose that diabetic patients with a MMSE score of 27 points or less should be examined by a neurological specialist at least once.
Regarding the relationship between drinking habits and cognitive function, several reports recently published have suggested that moderate drinking might prevent the development of AD and cognitive decline [18, 19] . The current data were in agreement with this hypothesis, based on the result that there was a larger number of patients with a history of habitual drinking in the MMSE-normal group of diabetic patients. However, drinking is often associated with deterioration of glycemic control, so that further studies which take into consideration the amounts of daily alcohol intake are necessary to arrive at any definitive conclusions.
The relationship between the use of diuretics and cognitive functional decline is still unclear. To the best of our knowledge there are no reports on a decrease in cognitive function related to the use of diuretics, although the above-mentioned MRC trial also reported no significant effect of diuretic therapy on the rate of progression of cognitive functional decline [20] .
There were significantly more patients with CI receiving diuretic therapy in the present study. This may be explained by the fact that their hypertension was more severe, and therefore more medicines including diuretics were necessary to control their high blood pressures.
In the group of subjects with low MMSE scores, elevated total cholesterol and the non-HDL cholesterol (Total cholesterol − HDL-cholesterol) levels suggested the strong possibility of a relationship between lipid metabolism disorders and cognitive dysfunction in diabetic subjects. The causal relationship between apolipoprotein E4 and AD has already been established [21, 22] . However, it was difficult to consider this relationship in the present study, because the apolipoprotein phenotype had only been examined in a few the final diagnoses of the patients in the present clinicbased study to be highly reliable, because they were confirmed by detailed examinations, including neuropsychological tests, and/or brain CT/MRI/SPECT, and examination by geriatric neurological specialists in all cases. Therefore, it is a matter of serious concern to us that all 8 subjects with scores of 23 points or less on MMSE were finally given a diagnosis of dementia. Moreover, we found that the majority of the patients in the group with scores of 24 to 27 points on MMSE, in which AD cannot be excluded, had MCI, a high risk factor for developing AD [10] .
Yaffe et al. [11] investigated the relationship between the level of HbA1c and the risk of development of MCI in menopausal subjects with diabetes. They reported that an increase in the level of HbA1c by 1% was associated with a 1.5 times higher risk of developing MCI, and a 1.4 times higher risk of developing dementia. They showed that blood glucose control is more effective for preventing MCI than dementia, and that it is therefore essential to accurately detect MCI in these subjects, because of the possible usefulness of lifestyle interventions and medical treatments to prevent its progression to AD.
In our study, 31% of the patients with a MMSE score of 24 to 27 points agreed to further detailed examination in which 29% were given a diagnosis of MCI. It may be reasonable to state that 8% to 10% of all diabetic patients without definite CI can be estimated to have MCI. This estimated prevalence rate is also higher than the MCI prevalence rate in the general population reported in a recent systematic review [12] .
Cukierman-Yaffe et al. demonstrated that dysglycemia is a risk factor for lower MMSE score, analyzing baseline data in the "Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial" and concurrent "Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease" trial [13] . In addition, some cross-sectional studies [14, 15] lend support to the contention that CI may correlate with worse glycemic control. However, no significant correlation was observed between the fasting blood glucose or HbA1c levels, and performance on MMSE in the present study. However, this may reflect screening bias because the number of patients enrolled was small, or may be attributed to the difference in MMSE cutoff values between the present and previous studies.
The MMSE, adopted in this study as a screening diabetes and cognitive dysfunction, taking into account lifestyle factors (including habitual drinking) and medication for hypertension and dyslipidemia.
